H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu AE04621 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Boehringer Ingelheim announced the launch of its corporate venture capital fund, the Boehringer Ingelheim Venture Fund (BIVF). The BIVF aims to invest in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.

GlaxoSmithKline (GSK) and Isis Pharmaceuticals Inc. announced a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

Pfizer Inc. released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines.

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

The Support Partners Program offered by Lilly USA shows individuals with depression ways to build their own support group, which, in turn, can help them better deal with their depression symptoms. The Support Partners Program can also help people better understand the illness and the importance of seeking help from a health care professional.

Data presented at the 59 th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate* compared to the current standard of care, warfarin, irrespective of a patient's risk profile for stroke.(1)